NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
42195-0121-06 | 42195-0121 | DEXAMETHASONE | TaperDex 6-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 19, 2018 | In Use | |
42195-0127-07 | 42195-0127 | dexamethasone | TaperDex 7-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 22, 2019 | In Use | |
42195-0149-12 | 42195-0149 | DEXAMETHASONE | TaperDex 12-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 19, 2018 | In Use | |
42195-0221-06 | 42195-0221 | Dexamethasone | TaperDex 6-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 19, 2018 | In Use | |
42195-0270-07 | 42195-0270 | Dexamethasone | TaperDex 7-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 22, 2019 | In Use | |
42195-0490-12 | 42195-0490 | Dexamethasone | TaperDex 12-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 19, 2018 | In Use | |
42195-0721-21 | 42195-0721 | Dexamethasone | DEXAMETHASONE 6-Day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 7, 2020 | In Use | |
42291-0024-12 | 42291-0024 | Abiraterone | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jan. 14, 2019 | In Use | |
42291-0073-60 | 42291-0073 | ABIRATERONE | ABIRATERONE ACETATE | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 29, 2021 | In Use | |
42291-0085-30 | 42291-0085 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | March 13, 2020 | In Use | ||
42291-0085-90 | 42291-0085 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Sept. 23, 2020 | In Use | ||
44087-4000-00 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-04 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-05 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-06 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-07 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-08 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-09 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
48102-0051-01 | 48102-0051 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 1, 2021 | Dec. 31, 2023 | No Longer Used |
48102-0051-20 | 48102-0051 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 1, 2021 | June 1, 2021 | No Longer Used |
48102-0051-40 | 48102-0051 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 1, 2021 | June 1, 2021 | No Longer Used |
45963-0538-30 | 45963-0538 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2007 | In Use | |
45963-0539-30 | 45963-0539 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2007 | In Use | |
44523-0182-08 | 44523-0182 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate Oral Solution | 25.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 28, 2019 | In Use | |
50090-0655-00 | 50090-0655 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 28, 2014 | In Use | |
50090-0655-01 | 50090-0655 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 22, 2018 | In Use | |
50090-0655-02 | 50090-0655 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 29, 2018 | In Use | |
50090-2522-01 | 50090-0655 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 30, 2018 | March 30, 2018 | In Use |
50090-1876-00 | 50090-1876 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | June 16, 2015 | In Use | ||
50090-1876-02 | 50090-1876 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | June 12, 2018 | In Use | ||
50090-1882-00 | 50090-1882 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | June 16, 2015 | In Use | ||
50090-1882-01 | 50090-1882 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 20, 2019 | In Use | ||
42291-0155-01 | 42291-0155 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 31, 2022 | In Use | |
42291-0770-50 | 42291-0770 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 22, 2020 | Dec. 31, 2023 | In Use |
42291-0870-01 | 42291-0870 | Tretinoin | Tretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Feb. 23, 2022 | In Use | |
42543-0970-25 | 42543-0970 | Hydrocortisone | Hydrocortisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 22, 2021 | In Use | |
42543-0971-06 | 42543-0971 | Hydrocortisone | Hydrocortisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 22, 2021 | In Use | |
42543-0972-06 | 42543-0972 | Hydrocortisone | Hydrocortisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 22, 2021 | In Use | |
50268-0761-11 | 50268-0761 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | In Use | |
50268-0761-12 | 50268-0761 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | In Use | |
50268-0762-11 | 50268-0762 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | In Use | |
50268-0762-12 | 50268-0762 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | In Use | |
50268-0694-15 | 50268-0694 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 27, 2018 | In Use | ||
50268-0527-15 | 50268-0527 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 26, 2021 | In Use | |
50268-0476-15 | 50268-0476 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct. 2, 2019 | In Use | ||
50268-0075-15 | 50268-0075 | ANASTROZOLE | ANASTROZOLE | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct. 11, 2019 | In Use | ||
50383-0042-24 | 50383-0042 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 27, 2003 | In Use | |
50383-0042-48 | 50383-0042 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 27, 2003 | In Use | |
51144-0002-12 | 51144-0002 | Tucatinib | TUKYSA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | April 17, 2020 | In Use | |
51144-0002-60 | 51144-0002 | Tucatinib | TUKYSA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | April 17, 2020 | In Use |
Found 10,000 results in 10 milliseconds — Export these results